Naosuke Yokomichi1, Tatsuya Morita2, Akihiro Nitto3, Naoko Takahashi4, Shingo Miyamoto5, Hiroyuki Nishie6, Junji Matsuoka7, Hiroki Sakurai8, Tatsuhiko Ishihara9, Masanori Mori10, Yoko Tarumi11, Asao Ogawa12. 1. Seirei Hospice, Shizuoka, Japan. 2. Seirei Hospice, Shizuoka, Japan; Department of Palliative and Supportive Care, Shizuoka, Japan; Palliative Care Team, Seirei Hospice, Seirei Mikatahara General Hospital, Shizuoka, Japan. 3. Psycho-Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan. 4. Department of Palliative Care, Tokyo, Japan. 5. Department of Oncology, Japanese Red Cross Medical Center, Tokyo, Japan. 6. Department of Anesthesiology and Resuscitology, Okayama City, Japan. 7. Department of Palliative Care, Okayama University Hospital, Okayama City, Japan. 8. Department of Palliative Care, St. Luke's International Hospital, Tokyo, Japan. 9. Department of Palliative Care, Okayama Saiseikai General Hospital, Okayama, Japan. 10. Department of Palliative Medicine, Seirei Hamamatsu General Hospital, Shizuoka, Japan. 11. Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada. 12. Psycho-Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: asogawa@east.ncc.go.jp.
Abstract
CONTEXT: The Edmonton Symptom Assessment System-revised (ESAS-r) is a brief and widely used symptom measurement tool. OBJECTIVES: To validate the Japanese version of the ESAS-r in Japanese patients with cancer. METHODS: We assessed the internal consistency, test-retest reliability, concurrent validity, and known-group validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS-r, M. D. Anderson Symptom Inventory, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. RESULTS: Cronbach's alpha coefficient of the Japanese version of the ESAS-r was 0.87. The intraclass correlation coefficient in the test-retest examination ranged from 0.82 to 0.91 for each symptom score and was 0.90 for the total score. Pearson correlation coefficients of each ESAS-r symptom score with corresponding M. D. Anderson Symptom Inventory and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items ranged from 0.45 to 0.80. The total score of the ESAS-r was significantly higher in patients with an Eastern Cooperative Oncology Group performance status of 2-4 than in those with a performance status of 0 and 1 (P < 0.0001). CONCLUSION: The Japanese version of the ESAS-r is a reliable and valid tool for measuring symptoms in Japanese adult patients with cancer.
CONTEXT: The Edmonton Symptom Assessment System-revised (ESAS-r) is a brief and widely used symptom measurement tool. OBJECTIVES: To validate the Japanese version of the ESAS-r in Japanese patients with cancer. METHODS: We assessed the internal consistency, test-retest reliability, concurrent validity, and known-group validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS-r, M. D. Anderson Symptom Inventory, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. RESULTS: Cronbach's alpha coefficient of the Japanese version of the ESAS-r was 0.87. The intraclass correlation coefficient in the test-retest examination ranged from 0.82 to 0.91 for each symptom score and was 0.90 for the total score. Pearson correlation coefficients of each ESAS-r symptom score with corresponding M. D. Anderson Symptom Inventory and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items ranged from 0.45 to 0.80. The total score of the ESAS-r was significantly higher in patients with an Eastern Cooperative Oncology Group performance status of 2-4 than in those with a performance status of 0 and 1 (P < 0.0001). CONCLUSION: The Japanese version of the ESAS-r is a reliable and valid tool for measuring symptoms in Japanese adult patients with cancer.